Skip Navigation


European Heart Journal Advance Access originally published online on May 7, 2008
European Heart Journal 2008 29(11):1342-1343; doi:10.1093/eurheartj/ehn203
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
29/11/1342    most recent
ehn203v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kindermann, M.
Right arrow Articles by Böhm, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kindermann, M.
Right arrow Articles by Böhm, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Sweet hearts die earlier—lessons from CHARM

Michael Kindermann and Michael Böhm*

Klinik für Innere Medizin III (Kardiologie, Angiologie, Internistische Intensivmedizin), Universitätsklinikum des Saarlandes, Kirrberger Straße, D-66421 Homburg/Saar, Germany

* Corresponding author. Tel: +49 6841 1623372, Fax: +49 6841 1623369, Email: boehm@med-in.uni-saarland.de

This editorial refers to ‘Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure. An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme’{dagger} by M.R. MacDonald et al., on page 1377

Footnotes

The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.

{dagger} doi:10.1093/eurheartj/ehn153 Back

The first 10% of the full text of this article appears below.

It has been recognized for nearly a quarter of a century that patients with diabetes who develop cardiovascular disease (CVD) suffer from a worse prognosis than do CVD patients without diabetes mellitus.1 Against this background, the news from the CHARM Investigators2 that diabetes is an independent predictor of cardiovascular morbidity and mortality, not only in heart failure patients with severe systolic dysfunction but also in those with preserved ejection fraction, is not a big surprise. Accelerated coronary atherosclerosis,3 abnormal platelet function, coagulation, fibrinolysis, and endothelial dysfunction which favour coronary thrombosis,4 and autonomic neuropathy associated with an increased rate of ventricular arrhythmia and sudden death5 are possible mechanisms which may independently from left ventricular systolic dysfunction contribute to an increased risk of fatal . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme
Michael R. MacDonald, Mark C. Petrie, Fumi Varyani, Jan Östergren, Eric L. Michelson, James B. Young, Scott D. Solomon, Christopher B. Granger, Karl Swedberg, Salim Yusuf, Marc A. Pfeffer, John J.V. McMurray, and and for the CHARM Investigators
EHJ 2008 29: 1377-1385. [Abstract] [Full Text]